Lesotho to revise national guidelines to include tenofovir first line

HIV Treatment Bulletin - Vol. 8, No. 8/9, August-September 2007

The most important changes in the revised Lesotho national ART guidelines will be:

• CD4 threshold for initiation of HAART will change from < 200 to < 350 cells/mm³
• First-line will change from d4T/3TC/nevirapine (or efavirenz) to tenofovir/3TC/EFV (or NVP), so that the regimens in order of “preference” will be:
• 1. TDF/3TC/EFV (except for women of child-bearing age not on reliable contraception, children, and people with pre-existing renal dysfunction)
  2. TDF/3TC/NVP
  3. AZT/3TC/EFV
  4. AZT/3TC/NVP
  5. d4T/3TC/EFV
  6. d4T/3TC/NVP
• PMTCT protocol will officially change from sd NVP to HAART for all pregnant women < 350 (AZT/3TC/NVP for < 250 and AZT/3TC/EFV for 250-350 after 1st trimester) and short-course AZT from 28 weeks (plus sd NVP and AZT600mg at onset of labour + tail protection for the mother + PEP for the baby, etc.) for those > 350 cells/mm³.

The revised guidelines are still in draft form but have been provisionally approved by the Director General of Health at the Ministry of Health and Social Welfare (MOHSW) and are awaiting final approval.

Comment

This will be the first country in Africa to include TDF first line. The PMTCT recommendations are also very good news. Viva Lesotho for being so progressive (and the Ministry of Health of their more affluent, landlocking neighbours take note).

2007-08-10
IB070808-31

©2007. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.